{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:05:43Z","timestamp":1744178743073},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.ijantimicag.2010.04.003","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T08:42:57Z","timestamp":1275986577000},"page":"111-113","source":"Crossref","is-referenced-by-count":7,"title":["Comparative in vitro activity of ceftobiprole against Gram-positive cocci"],"prefix":"10.1016","volume":"36","author":[{"given":"Carmen","family":"Betriu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Culebras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1tima","family":"L\u00f3pez-Fabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iciar","family":"Rodr\u00edguez-Avial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Picazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2010.04.003_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2007.09.012","article-title":"Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time\u2013kill analysis","volume":"60","author":"Lin","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.diagmicrobio.2007.02.010","article-title":"In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection","volume":"58","author":"Rouse","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/jac\/dkp176","article-title":"Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model","volume":"64","author":"Zhanel","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib4","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1128\/AAC.49.10.4210-4219.2005","article-title":"Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin","volume":"49","author":"Bogdanovich","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib5","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1128\/AAC.49.5.1932-1942.2005","article-title":"Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin","volume":"49","author":"Kosowska","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib6","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M7-A8. Wayne, PA: CLSI; 2009."},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib7","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009."},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/jac\/dkf249","article-title":"In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci","volume":"50","author":"Jones","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jac\/dkm492","article-title":"In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin","volume":"61","author":"Pillar","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2008.02.008","article-title":"Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005\u20132006)","volume":"61","author":"Fritsche","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib11","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/AAC.00336-08","article-title":"In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections","volume":"52","author":"Amsler","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.diagmicrobio.2007.06.023","article-title":"Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees","volume":"59","author":"Yun","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.diagmicrobio.2008.03.004","article-title":"The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials","volume":"61","author":"Deresinski","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.04.003_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.diagmicrobio.2008.02.013","article-title":"Pharmacokinetic and pharmacodynamic profile of ceftobiprole","volume":"61","author":"Lodise","year":"2008","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910001780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910001780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T15:23:22Z","timestamp":1544455402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857910001780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0924857910001780"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.04.003","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}